Moreover, authors demonstrated that oncogenicity derived from METTL3 activity is due to changes in alternative splicing events of genes with relevant implications in cancer cell death and migration, like BCL-X and NCOR2. Altogether, this clearly indicates that dysregulated AS events in cancer cells contribute for the involvement of NMD in cancer development and/or progression. This evidence concerns the gene METTL3 and cancer.